PaxMedica Inc

PaxMedica, Inc. is an early clinical stage biopharmaceutical company. It focuses on the development of anti-purinergic therapies for the treatment of neurodevelopmental disorders, including autism spectrum disorder and Fragile X syndrome tremor-ataxia. The company was founded in April 5, 2018 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN --  PaxMedica , Inc. (Nasdaq: PXMD ) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatry, an internationally recognized scientific psychiatry publication, has accepted the manuscript titled "Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder" for publication.

PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication

ABVC BioPharma

Vaccinex Inc

If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market.

Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch

Key Guidance Regarding NDA Filing Obtained TARRYTOWN, NY / ACCESSWIRE / October 26, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company, announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated.

PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

Presentation on Tuesday, September 12, 2023 at 3:00pm EDT TARRYTOWN, NY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that it will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY.

PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced the return of David Hough, M.D., as Chief Medical Officer (CMO) of PaxMedica, effective immediately.

PaxMedica Appoints David Hough M.D. as Chief Medical Officer

TARRYTOWN, NY, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023.

PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update

PaxMedica to discuss significance of Phase 3 study results Interview to be webcast on Tuesday, August 15, 2023, at 10:30 am ET TARRYTOWN, NY, August 8, 2023 – PaxMedica, Inc.

PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study

TARRYTOWN, NY, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced positive top line data for the Company's PAX-HAT-301 Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (S1 TBR HAT).

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as well as additional offerings for People diagnosed with Autism and their Families.

PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC

Shares of PaxMedia Inc. PXMD, -11.91% bounced 2.0% in premarket trading Thursday, after the biopharmaceutical company, which focuses on treatments of Autism Spectrum Disorder (ASD) said it was not aware of any news that might have led to the recent selloff in its stock. The company said it has hired Shareholder Intelligence Services LLC (ShareIntel) to look into the recent price fluctuations.

PaxMedia hires ShareIntel to look into recent stock weakness, after a 45% plunge amid an 8-day losing streak

Engages ShareIntel to Track Market Activity TARRYTOWN, NY, June 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that the management and Board of Directors of PaxMedica are aware of the recent market volatility in the company's common stock.  PaxMedica is not aware of any news that might be relevant to the recent share price fluctuations, however management takes its fiduciary responsibility very seriously, and have engaged the services of Shareholder Intelligence Services LLC (“ShareIntel”) to better understand the investor base and the trading behavior around the company's securities.

PaxMedica Comments on Common Stock Volatility

Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that its CEO, Howard Weisman, participated in a webcast on Saturday, June 17th, hosted by The BRAIN Foundation.  The core content of the webcast was an interview with Mr.

PaxMedica CEO Interviewed by The BRAIN Foundation

TARRYTOWN, NY, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that it has submitted a request to the South African Health Products Regulatory Authority (SAHPRA), seeking approval to conduct a double-blind, placebo-controlled study, PAX-ASD-101.  This trial will seek to enroll a total of 30 subjects with confirmed ASD, ages 4 to 18, at multiple sites in South Africa.  This is the first new clinical trial on the safety, tolerability, and efficacy of suramin since the Company announced the results of its prior Phase II trial in 2021. Enrollment is expected to begin in Q4 2023, following SAHPRA's potential approval later this summer.

PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder

Collaboration Will Investigate a Next Generation Orally Delivered Anti-Purinergic Compound Proof-of-Concept Study Based on one of PaxMedica's Proprietary Pipeline Candidates TARRYTOWN, NY, June 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that it has entered into an agreement with PoloMar Health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder. Emodin is an orally bioavailable selective P2X7 inhibitor, and is currently available as a component in a number of over-the-counter nutritional supplements.

PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder

HAT-301 is the Pivotal Efficacy Study to Support Upcoming NDA Filing Top Line Results Planned for Release in July 2023 TARRYTOWN, NY, June 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD), and other serious conditions with intractable neurologic symptoms, today announced that the eligibility review and final enrollment for the company's Real World Evidence study (HAT-301) has been completed. Patient eligibility was assessed for inclusion by an Independent Study Adjudication Committee which included a total of three subject matter expert medical reviewers.

PaxMedica Completes HAT-301 Registrational Trial for PAX-101

TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023.

PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023

Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that Chief Executive Officer Howard Weisman will ring the Nasdaq Stock Market closing bell on Wednesday April 19, 2023. This comes to celebrate PaxMedica's listing of its common shares on the Nasdaq Capital Market in August 2022 and April's Autism Awareness Month.

PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month

-Phase 3 Results for HAT-301 Retrospective Trial Expected in Second Half 2023-

PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results

Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S.

PaxMedica Holds Meeting of Scientific Advisory Board

Cingulate

Karyopharm Therapeutics

Short squeeze penny stocks to watch. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch

Beyond Meat

Carvana

EVgo

Root

Silvergate Capital Corp

Upstart Holdings

Search queries focusing on stocks with the highest short interest this week are generating tremendous buzz. Few other subsegments within the capital market enable regular retail investors to enjoy enormous upside within a condensed period.

7 Stocks With the Highest Short Interest This Week

Company Anticipates Multiple Milestones in Next 12-24 Months

PaxMedica Releases 2022 Shareholder Letter

Crown ElectroKinetics

Inovio Pharmaceuticals

Should penny stocks be on your watchlist? The post Are Penny Stocks on Your February Watchlist?

Are Penny Stocks on Your February Watchlist? 3 Reasons to Buy

AMC Preferred Equity Unit

Faraday Future Intelligent Electric

Here's some tips for deciding which penny stocks are worth buying The post Deciding Which Penny Stocks to Buy? Use These 3 Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Deciding Which Penny Stocks to Buy? Use These 3 Tips

Genetic Technologies

Gracell Biotechnologies

GeneDx Holdings Corp

Penny stocks with news to watch this week. The post Penny Stocks To Buy: 4 To Watch With Big News In February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for PaxMedica Inc Stock (PXMD)